Tenofovir Anhydrous
drugOn this page
Also known as GS-1275tenofovirtdfTenofovirÊTenofovirÂC0088679
Summary
Tenofovir Anhydrous (CHEMBL483) is an approved small-molecule HIV-1 reverse transcriptase inhibitor; indicated across 10 conditions including hiv infectious disease and aids.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 10 conditions
- Clinical trials: 286
- Chemistry: 287.21 Da · C9H14N5O4P
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL483 |
| Name | Tenofovir Anhydrous |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 464205 |
| ChEBI | CHEBI:63625 |
| Molecular formula | C9H14N5O4P |
| Molecular weight | 287.21 |
| InChIKey | SGOIRFVFHAKUTI-ZCFIWIBFSA-N |
SMILES: C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O
IUPAC name: [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
ChEBI definition: A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.
Pharmacological roles (ChEBI): HIV-1 reverse transcriptase inhibitor, antiviral drug.
Other ChEBI roles (chemical / environmental): drug metabolite.
Also known as: GS-1275, Tenofovir anhydrous, tenofovir, Tenofovir, tdf, TENOFOVIR ANHYDROUS, TENOFOVIR, TenofovirÊ, TenofovirÂ, C0088679
Parent form; salt/anhydrous children: CHEMBL3989702
Patent coverage: 8,295 distinct patent families (29,740 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 29,483 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Cytochrome P450 3A4.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| HIV infectious disease | 3 | MONDO:0005109 | EFO:0000180 |
| AIDS | 3 | MONDO:0012268 | EFO:0000765 |
| hepatitis B virus infection | 3 | MONDO:0005344 | EFO:0004197 |
| chronic hepatitis B virus infection | 3 | MONDO:0005366 | EFO:0004239 |
| hepatitis D virus infection | 3 | MONDO:0005789 | EFO:0007304 |
| hepatocellular carcinoma | 3 | MONDO:0007256 | EFO:0000182 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
| chronic hepatitis C virus infection | 1 | MONDO:0005354 | EFO:0004220 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 286.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 80 |
| PHASE4 | 68 |
| PHASE2 | 45 |
| Not specified | 39 |
| PHASE1 | 36 |
| PHASE1/PHASE2 | 8 |
| PHASE2/PHASE3 | 6 |
| EARLY_PHASE1 | 4 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02656511 | PHASE4 | ACTIVE_NOT_RECRUITING | Immediate Initiation of Antiretroviral Therapy During Hyperacute HIV Infection |
| NCT06743438 | PHASE4 | ACTIVE_NOT_RECRUITING | Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB |
| NCT00038506 | PHASE4 | COMPLETED | Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure |
| NCT00127959 | PHASE4 | COMPLETED | Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection |
| NCT00192595 | PHASE4 | COMPLETED | Tenofovir in HIV/HBV Coinfection |
| NCT00192660 | PHASE4 | COMPLETED | HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001) |
| NCT00244712 | PHASE4 | COMPLETED | Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV |
| NCT00344461 | PHASE4 | COMPLETED | A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine |
| NCT00344760 | PHASE4 | COMPLETED | A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy |
| NCT00358696 | PHASE4 | COMPLETED | Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients |
| NCT00386659 | PHASE4 | TERMINATED | Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz. |
| NCT00409019 | PHASE4 | WITHDRAWN | Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy |
| NCT00444379 | PHASE4 | COMPLETED | Anti-Retrovirals for Kaposi’s Sarcoma |
| NCT00532168 | PHASE4 | COMPLETED | Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl |
| NCT00544128 | PHASE4 | COMPLETED | Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment |
| NCT00549198 | PHASE4 | COMPLETED | KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects |
| NCT00615745 | PHASE4 | COMPLETED | ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla |
| NCT00643968 | PHASE4 | COMPLETED | Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial |
| NCT00651209 | PHASE4 | COMPLETED | A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB) |
| NCT00677300 | PHASE4 | COMPLETED | Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients |
| NCT00759070 | PHASE4 | UNKNOWN | Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism |
| NCT00869960 | PHASE4 | COMPLETED | Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women |
| NCT00924898 | PHASE4 | COMPLETED | Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805) |
| NCT00931801 | PHASE4 | COMPLETED | BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated. |
| NCT01014481 | PHASE4 | TERMINATED | Appropriate Timing of HAART in Co-infected HIV/TB Patients |
| NCT01232127 | PHASE4 | COMPLETED | Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection |
| NCT01270802 | PHASE4 | COMPLETED | Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients |
| NCT01277601 | PHASE4 | COMPLETED | Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B |
| NCT01320943 | PHASE4 | COMPLETED | Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB |
| NCT01332227 | PHASE4 | COMPLETED | Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients |
| NCT01335620 | PHASE4 | COMPLETED | The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age |
| NCT01448616 | PHASE4 | COMPLETED | Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding |
| NCT01529749 | PHASE4 | COMPLETED | Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated |
| NCT01533272 | PHASE4 | COMPLETED | Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) |
| NCT01576731 | PHASE4 | COMPLETED | Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP) |
| NCT01588912 | PHASE4 | UNKNOWN | Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir |
| NCT01601899 | PHASE4 | TERMINATED | Differences Between Stavudine and Tenofovir Each Combined With Lamivudine and Efavirenz in SA HIV-infected Patients |
| NCT01639066 | PHASE4 | COMPLETED | Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B |
| NCT01639092 | PHASE4 | COMPLETED | Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B |
| NCT01694017 | PHASE4 | COMPLETED | Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 17 clinical and 109 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).